Distigmine

DB13694InvestigationalSmall molecule

Distigmine is a cholinesterase inhibitor indicated in the treatment of neurogenic bladder dysfunction or myasthenia gravis. Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to DB00545 and DB01400.

Mechanism: Pharmacologically active on Acetylcholinesterase
Curator reviewed
Formula / weight: C₂₂H₃₂N₄O₄ · 416.521 g/mol (avg)

Resolves to

Compound

UNIIT940307O7BCAS17299-00-2ChEMBLCHEMBL1199307ChEBI80756PubChem3116KEGGC16823

Clinical / RWD

RxNorm3551ATCN07AA03

Structure

InChIKeyAHZBEVXBKNYXPU-UHFFFAOYSA-NSMILESCN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1

Targets

P22303ACHE

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

292Drug interactionsStructured to mechanism, not free text

2Structured indicationsCondition, population, route and combination as fields, not prose

18ContraindicationsEach with its own population and attribute set

3Marketed productsAcross 2 countries and 2 labellers

1ATC codeIncluding every combination product, plus 7 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Distigmine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account